Article

Study Underscores Harm From Unregulated Marketing of Genetic Tests

The study, conducted at the Dana-Farber Cancer Institute and published in the Journal of the National Cancer Institute found that the benefits of these personalized cancer products are reported much more frequently than are the limitations.

Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute.

Internet marketing of cancer-related gene tests is unregulated. Therefore, there is wide variation in how these services are presented—posing a challenge for consumers and their physicians, the researchers reported in the March 5, 2015 issue of the Journal of the National Cancer Institute.

“We wanted to see if consumers are getting a balanced picture of benefits and limitations of these services,” said Stacy Gray, MD, AM, first author of the report analyzing 55 websites marketing the services. “We found a lot of variation. Some of the information is good, but all of it needs to be looked at critically by consumers and health care providers.”

Read the complete news release by the Dana-Farber Cancer Insitute: http://bit.ly/1BOC0Eg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo